Clozapine is a second-generation antipsychotic drug proven to be effective on treatment-resistant schizophrenia. Among patients using clozapine; the incidence of neutropenia is approximately 3% and the incidence of agranulocytosis is approximately 1%. This side effect is diminishing after 18 weeks of drug initiation. In this case, the clozapine-induced neutropenia after 7 years of clozapine use in the schizophrenic patient and its treatment with lithium supplementation will be presented.
Clozapine, neutropenia, lithium
Article Language: Turkish English